Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00695 ...
Drug Name Furosemide
Molecular Weight 330.744
Molecular Formula C12H11ClN2O5S
CAS Number 54-31-9
SMILES NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
External Links
DRUGBANK DB00695
PubChem Compound 3440
PDR 1557
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Caco-2 Permeability -6.5 - -6.5 - ADME Research, USCD
Log P 2.03 - 2.03 - SANGSTER (1993)
Melting Point 220.0 ℃ 220 ℃ MSDS
Water Solubility 73.1 mg/L 73.1 mg/L YALKOWSKY,SH & DANNENFELSER,RM 1992)
Log S -3.66 - -3.66 - ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 50.0 % 10-90 % PO, oral; extended release formulation; DRUGBANK
Bioavailability 64.0 % 64 % Tablet, PO, oral; DRUGBANK
Bioavailability 60.0 % 60 % Capsule, PO, Oral; DRUGBANK
Bioavailability 71.0 % 71±35(43-73) % PO, oral; Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 1700.0 ng/ml 1.7±0.9 mcg/ml Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.4 h 1.4±0.8 h Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Metabolic 85.0 % 85 % Urinary excretion; DRUGBANK
Clearance 0.0738 L/h/kg 1.23 ml/min/kg Plasma clearance; intravenous injection, IV; heart disease; patients; DRUGBANK
Clearance 0.14 L/h/kg 2.34 ml/min/kg Plasma clearance; intravenous injection, IV; normal,healthy; DRUGBANK
Clearance 0.14 L/h/kg 1.5-3.0 ml/min/kg Neonates ↓ ;Elderly ↓ ;Prem, premature ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis ↑ ;congestive heart disease ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.0960 L/h/kg 1.6 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 0.18 L/kg 0.181 L/kg intravenous injection, IV; normal,healthy; DRUGBANK
Volume of Distribution 0.14 L/kg 0.14 L/kg intravenous injection, IV; heart disease; patients; DRUGBANK
Volume of Distribution 0.13 L/kg 0.09-0.17 L/kg Neonates ↑ ;Prem, premature ↑ ;Elderly → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;congestive heart disease → ;nephritic syndrome ↑ ;Somking → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.12 L/kg 0.12 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 4.0 h 4 h PO, oral; DRUGBANK
Half-life 4.5 h 4.5 h intravenous injection, IV; DRUGBANK
Half-life 2.0 h ~2 h terminal half-life; parenteral administration; DRUGBANK
Half-life 24.0 h 24 h terminal half-life; severe renal failure; DRUGBANK
Half-life 1.3 h 1.3±0.8(0.5-2.0) h normal,healthy; Male, men; Prem, premature ↑ ;Neonates ↑ ;mild renal function ↑ ;congestive heart disease ↑ ;Hepatic cirrhosis, cirr ↑ ;nephritic syndrome → ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 2.5 h 2.5 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 2600.0 mg/kg 2600.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 800.0 mg/kg 800.0 mg/kg Intraperitoneal, IP; Rattus, Rat; DRUGBANK
Toxicity LD50 4600.0 mg/kg 4600.0 mg/kg subcutaneous injection, SC; Rattus, Rat; DRUGBANK
Toxicity TDLo 6.3 mg/kg 6250.0 ug/kg  Female, women; DRUGBANK
Eliminate Route 43.0 % ~43 % Urinary excretion; DRUGBANK
Eliminate Route 50.0 % ~50 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 71.0 % 71±10 % Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; Elderly → ;Cystic fibrosis ↓ ; The Pharmacological Basis of Therapeutics
Eliminate Route 65.0 % 50-80 % Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 95.0 % ~91-99 % normal,healthy; DRUGBANK
Protein Binding 97.5 % 96-99 % adults; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics
Protein Binding 98.6 % 98.6±0.4 % adults; normal,healthy; human, homo sapiens; Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;nephritic syndrome ↓ ;hypoalbuminemia Alb ↓ ;congestive heart disease → ;Somking → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Frequency Brand Name Component Reference
Max dose for neonates 4.0 mg/kg/day 2 mg/kg/dose/day intravenous injection, IV bid Furosemide Injection furosemide PDR
Max dose for neonates 1.0 mg/kg/dose/day 1 mg/kg/dose/day intravenous injection, IV Furosemide Injection furosemide PDR
Max dose for infants 6.0 mg/kg/dose 6 mg/kg/dose PO, oral;intravenous injection, IV; Furosemide Injection furosemide PDR
Max dose for children 6.0 mg/kg/dose 6 mg/kg/dose PO, oral;intravenous injection, IV; Furosemide Injection furosemide PDR
Max dose for adolescents 6.0 mg/kg/dose 6 mg/kg/dose PO, oral;intravenous injection, IV; Furosemide Injection furosemide PDR
Max dose for adults 600.0 mg/day 600 mg/day PO, oral Furosemide Injection furosemide PDR
Max dose for adults 6000.0 mg/day 6 g/day intravenous injection, IV Furosemide Injection furosemide PDR
Max dose for adults 4000.0 mg/day 4 g/day PO, oral Furosemide Injection furosemide PDR
Max dose for geriatric 600.0 mg/day 600 mg/day PO, oral Furosemide Injection furosemide PDR
Max dose for geriatric 6000.0 mg/day 6 g/day intravenous injection, IV Furosemide Injection furosemide PDR
Max dose for geriatric 4000.0 mg/day 4 g/day PO, oral Furosemide Injection furosemide PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1